ClinicalTrials.gg
CompletedNCT05375929Updated Oct 15, 2024Results posted

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

A Phase 3 interventional study of Abrocitinib 100 mg and Abrocitinib 200 mg in Atopic Dermatitis, sponsored by Pfizer. Completed at 15 sites in India. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
10th of 20
200 · median 150
Started
2022
with 1 other
Phase 3
10 of 20
2 open now
Registered
13th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 10th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 3, and was the 13th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India. AD, also known as atopic eczema, is a chronic, relapsing skin condition characterized by dry, itchy skin lesions which can affect any part of the body. Adult peoples who participate in this study will take either 100 mg or 200 mg of abrocitinib tablets by mouth for a duration of 12 weeks and adolescents will take for duration of 52 weeks. Knee Magnetic Resonance Imagine (MRI) will be done on adolescent peoples to determine bone safety findings. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and how well they work.

Read the detailed description

Abrocitinib is an oral, once daily Janus kinase 1 (JAK1) selective inhibitor for the treatment of moderate to severe Atopic Dermatitis (AD). Selective inhibition of JAK1 with abrocitinib modulates signaling by Interleukin-4 (IL-4), Interleukin (IL-13), and other cytokines [eg, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP)] involved in the pathogenesis of Atopic Dermatitis and pruritus.

This is a randomized, open label, parallel group study to assess the safety and efficacy of orally administered tablets of abrocitinib in participants aged 12 years and older with moderate to severe AD in India. There is a planned treatment duration of 12 weeks, with 4 weeks of off-treatment safety follow up thereafter.

This study protocol also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee magnetic resonance imaging (MRI). Adolescent participants (12 to \<18 years of age) will continue to receive study intervention until 1 year after randomization into the main study.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • AD
  • Atopic Eczema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

This study is seeking participants who:

  1. Must be of 12 years of age or older, at the time of .
  2. Meet all the following Atopic Dermatitis (AD) criteria:

    • Clinical diagnosis of chronic AD (also known as atopic eczema) for at least 1 year prior to Day 1 and has confirmed AD (Hanifin and Rajka criteria of AD10).
    • Moderate to severe AD (affected body surface area (BSA) ≥10%, Investigator's Global Assessment (IGA) ≥3, Eczema Area and Severity Index (EASI) ≥16, and Peak Pruritus Numerical Rating Scale (PP-NRS) ≥4 at the baseline visit);
    • Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications for at least 4 weeks, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks), or who have required systemic therapies for control of their disease.
  3. Negative pregnancy test for females of at Screening. Female participants of childbearing potential must agree to use a highly effective method of for the duration of the active treatment period and for at least 28 days after the last dose of study intervention.
  4. Body weight ≥25 kg at Baseline
  5. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Document (ICD) and in this protocol. Evidence of a personally signed and dated ICD indicating that the participant (or a legally acceptable representative, parent(s)/legal guardian) has been informed of all pertinent aspects of the study. For minors under the age of legal consent in India, assent of the participating child needs to be documented for the age range 12 to 18 years in addition to the parental informed consent.

Exclusion criteria

Exclusion Criteria:

This study does not include participants who:

  1. Currently have active forms of other inflammatory skin diseases or have evidence of skin conditions (eg, psoriasis, seborrheic dermatitis, lupus).
  2. A current or past medical history of conditions associated with thrombocytopenia, coagulopathy or dysfunction or abnormalities.
  3. Have increased risk of developing venous thromboembolism, eg, deep vein thrombosis or pulmonary embolism:
  4. Have a history of any lymphoproliferative disorder such as Epstein Barr virus (EBV) related lymphoproliferative disorder, history of lymphoma, leukemia, or signs or symptoms suggestive of current lymphatic or lymphoid disease.
  5. Past history or active infection with Mycobacterium tuberculosis (TB), disseminated herpes zoster or disseminated herpes simplex, (HIV), , or .
  6. Have any or have a history of malignancies with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
  7. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgement, make the participant inappropriate for the study. Any psychiatric condition including recent or active suicidal ideation or behavior that met any of the following criteria when screened for during the main study:

    • Suicidal ideation associated with actual intent and a method or plan in the past year: "Yes" answers on items 4 or 5 of the Columbia suicide severity rating scale (C-SSRS);
    • Previous history of suicidal behaviors in the past 5 years: "Yes" answer (for events that occurred in the past 5 years) to any of the suicidal behavior items of the C-SSRS;
    • Any lifetime history of serious or recurrent suicidal behavior;
    • The presence of any current major psychiatric disorder that is not explicitly permitted in the inclusion/exclusion criteria;
    • In the opinion of the investigator or Pfizer (or designee) exclusion is required.
  8. Prior treatment with systemic janus kinase (JAK) inhibitors.
  9. Participants who are vaccinated with within the 6 weeks prior to the first dose of abrocitinib or who are expected to be vaccinated with these vaccines during treatment or during the 6 weeks following discontinuation of abrocitinib.
  10. Have received any of the following treatment regimens specified in the timeframes outlined below:

    Within 1 year of first dose of study intervention:

    • Prior treatment with non B cell-specific lymphocyte depleting agents/therapies (eg, alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation, etc.). Participants who have received rituximab or other selective B lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to study baseline and have normal cluster of differentiation (CD) 19/20+ counts by fluorescence activated cell sorting (FACS) analysis.

    Within 12 weeks of first dose of study intervention:

    • Biologic drugs that have immunomodulatory properties or could be used to treat AD: within 12 weeks of first dose of product or 5 half-lives (if known), whichever is longer.

    Other biologics without immunomodulatory properties (eg, insulin) are permissible at the judgement of the Investigator.

    Within 4 weeks of first dose of study intervention:

    • Use of oral drugs (eg, Cyclosporine A (CsA), azathioprine, methotrexate, systemic , mycophenolate mofetil, Interferon gamma) within 4 weeks of first dose of study intervention or within 5 half-lives (if known), whichever is longer.

    NOTE: Systemic corticosteroids must be discontinued before Study Day 1, but a specific timeframe for discontinuation prior to first dose of abrocitinib is not required.

    NOTE: Corticosteroid inhalers and intranasal sprays are permissible. NOTE: Ophthalmic corticosteroids are permissible.

    Within 1 week of first dose of study intervention:

    • Anti-platelet drugs. Note: low dose acetyl salicylic acid (\<100 mg once daily [QD]) is permitted, for the purpose of cardiovascular prophylaxis, at the discretion of the investigator.
  11. Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication.
  12. Participation in other studies involving investigational drug(s) or vaccine within 8 weeks or within 5 half-lives (if known) whichever is longer, prior to study entry and/or during study participation.
  13. Any of the following abnormalities in clinical laboratory tests at Screening:

    • of \<1.0 × 109/L (\<1000/mm3);
    • Platelet count of \<150 × 109/L (\<150,000/mm3);
    • Absolute lymphocyte count of \<0.50 × 109/L (\<500/mm3);
    • Estimated \<60 mL/min using the Cockcroft Gault method;
    • (AST) or Alanine Aminotransferase (ALT) values >2 times the (ULN);
    • Total (TBili) ≥1.5 times the ULN.
  14. Pregnant or breastfeeding women, or women of who are unwilling to use highly effective consistently and correctly for the entire duration of the study and for at least 28 days after the last dose of study intervention.
  15. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Abrocitinib 100 mg

    Participants will receive abrocitinib 100 mg by mouth (QD).

    Drug: Abrocitinib 100 mg

  • Experimental
    Abrocitinib 200 mg

    Participants will receive abrocitinib 200 mg QD.

    Drug: Abrocitinib 200 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Main Study

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other situations where medical or scientific judgement should be exercised by investigator. AEs included SAEs and all non-SAEs.

    Time frame: From Day 1 of dosing up to 4 weeks post last dose (maximum up to Week 16)

Secondary outcomes

  1. Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and >= 2 Points Improvement From Baseline at Week 12: Main Study

    IGA assesses severity of AD on a 5-point scale (0 to 4: higher scores = more severity). Scores: 0= clear (no AD inflammatory signs except for any residual discolouration \[post-inflammatory hyperpigmentation and/or hypopigmentation\]); 1= almost clear (AD not entirely cleared- light pink residual lesions \[except post-inflammatory hyperpigmentation\], just barely perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting); 2= mild (AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting); 3= moderate (AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting); 4= severe (AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting). \>=2 points improvement from baseline: decrease of at least 2 points in IGA score from baseline at Week 12.

    Time frame: Baseline (prior to dosing on Day 1), Week 12

  2. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >= 75% Improvement From Baseline at Week 12: Main Study

    EASI evaluates severity of participant's AD based on both severity of lesion clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) scored separately for each of 4 body regions (head and neck \[h\], upper limbs \[u\], trunk \[t\]-\[including axillae and groin\] and lower limbs \[l\]-\[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + ExU + Lu) + 0.3\*At\*(Et + It + Ext + Lt) + 0.4\*Al\*(El + Il + Exl +Ll); A = EASI area score. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. \>=75% improvement from baseline: decrease of 75% in EASI score from Baseline at Week 12.

    Time frame: Baseline (prior to dosing on Day 1), Week 12

  3. Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >= 75% Improvement From Baseline at Week 12: Main Study

    SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. Score for each body region was added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; lichenification; dryness) assessed as none =0, mild =1, moderate =2, severe =3. Severity scores were added to give B (0-18). C: pruritus and sleep, each was scored by participant/caregiver using visual analogue scale (VAS) where 0= no itch/no sleeplessness and 10= worst imaginable itch/sleeplessness. Scores for itch and sleeplessness were added to give C (0-20). Total SCORAD was calculated: A/5 + 7\*B/2 + C; total SCORAD range from 0-103; higher SCORAD scores = greater severity of AD. \>=75% improvement from baseline: decrease of 75% in SCORAD score from Baseline at Week 12.

    Time frame: Baseline (prior to dosing on Day 1), Week 12

  4. Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score at Weeks 2, 4, 8 and 12: Main Study

    POEM is a 7-item participant reported outcome (PRO) measure to assess the impact of AD over the past week. Items were: dryness or roughness of skin in day, skin being itchy in day, skin flaking off in day, skin cracking in day, skin bleeding in day, skin weeping or oozing in day and sleep disturbed in night. Each item is scored from 0 to 4, depending on number of days/night (for sleep items) over the past week symptoms happened, where 0= no days, 1= "1-2 days", 2= "3-4 days", 3= "5-6 days" and 4= "every day". Scores from all items are added up, which results in POEM score, ranging from 0 to 28, where higher scores indicate greater severity of AD and greater symptom burden.

    Time frame: Baseline (prior to dosing on Day 1), Weeks 2, 4, 8 and 12

  5. Change From Baseline in Atopic Dermatitis Control Tool (ADCT) Score at Weeks 2, 4, 8 and 12: Main Study

    ADCT score is used to measure the participants perceived AD control. It consists of 6 questions (overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions) which are evaluated over the past week on scale from 0 to 4. Scores from all 6 questions are added up to provide ADCT score, ranging from 0 to 24, where higher scores indicate lower AD control.

    Time frame: Baseline (prior to dosing on Day 1), Weeks 2, 4, 8 and 12

  6. Percentage of Participants With Bone Safety Findings in Knee Magnetic Resonance Imaging (MRI) at 1 Year After Randomization: Substudy

    MRI imaging session was performed when participant was in supine position in the confined space of the MRI scanner for approximately 30 mins. The assessments included evaluation of epiphyseal plate closure and mineralization of cartilage at the growth centers.

    Time frame: Up to 1 year from randomization on Day 1 of main study

07

Results

Posted Sep 19, 2024
Limitations and caveats
One participant was randomized to abrocitinib 200 mg arm but received abrocitinib 100 mg, hence for safety analysis set of main study that participant was included in 100 mg arm and for full analysis set that participant was included in 200 mg arm.

Participant flow

A total of 200 participants aged greater than or equal to (\>=) 12 years with moderate to severe atopic dermatitis (AD) were enrolled in the study.

Main Study: Treatment Phase (12 Weeks)
Participant flow — Main Study: Treatment Phase (12 Weeks)
MilestoneMain Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDSubstudy: Abrocitinib 200 mgSubstudy: Abrocitinib 100 mg
Started9910100
Safety analysis set9910100
Full analysis set10010000
Completed919400
Not completed8700
Withdrew: Adverse event1000
Withdrew: Lost to follow-up1100
Withdrew: Withdrawal by subject6500
Withdrew: Withdrawal by parent/guardian0100
Main Study: Follow-up (4 Weeks)
Participant flow — Main Study: Follow-up (4 Weeks)
MilestoneMain Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDSubstudy: Abrocitinib 200 mgSubstudy: Abrocitinib 100 mg
Started919400
Completed909300
Not completed1100
Withdrew: Lost to follow-up1000
Withdrew: Did not complete study follow-up0100
Substudy: Treatment Phase (1 Year)
Participant flow — Substudy: Treatment Phase (1 Year)
MilestoneMain Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDSubstudy: Abrocitinib 200 mgSubstudy: Abrocitinib 100 mg
Started001916
Completed001215
Not completed0071
Withdrew: Withdrawal by parent/guardian0001
Withdrew: Physician decision0040
Withdrew: Lost to follow-up0010
Withdrew: Adverse event0020
Substudy: Follow-up (4 Weeks)
Participant flow — Substudy: Follow-up (4 Weeks)
MilestoneMain Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDSubstudy: Abrocitinib 200 mgSubstudy: Abrocitinib 100 mg
Started001715
Completed001715
Not completed0000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Main Study

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other situations where medical or scientific judgement should be exercised by investigator. AEs included SAEs and all non-SAEs.

Time frame:
From Day 1 of dosing up to 4 weeks post last dose (maximum up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Main Study
ParticipantsMain Study: Abrocitinib 200 mgMain Study: Abrocitinib 100 mg
AEs3026
SAEs01
SecondaryPercentage of Participants Who Achieved Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and >= 2 Points Improvement From Baseline at Week 12: Main Study

IGA assesses severity of AD on a 5-point scale (0 to 4: higher scores = more severity). Scores: 0= clear (no AD inflammatory signs except for any residual discolouration \[post-inflammatory hyperpigmentation and/or hypopigmentation\]); 1= almost clear (AD not entirely cleared- light pink residual lesions \[except post-inflammatory hyperpigmentation\], just barely perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting); 2= mild (AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting); 3= moderate (AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting); 4= severe (AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting). \>=2 points improvement from baseline: decrease of at least 2 points in IGA score from baseline at Week 12.

Time frame:
Baseline (prior to dosing on Day 1), Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and >= 2 Points Improvement From Baseline at Week 12: Main Study
Percentage of participantsMain Study: Abrocitinib 200 mgMain Study: Abrocitinib 100 mg
Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and >= 2 Points Improvement From Baseline at Week 12: Main Study48.5 (38.6 to 58.3)50.0 (40.2 to 59.8)
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >= 75% Improvement From Baseline at Week 12: Main Study

EASI evaluates severity of participant's AD based on both severity of lesion clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) scored separately for each of 4 body regions (head and neck \[h\], upper limbs \[u\], trunk \[t\]-\[including axillae and groin\] and lower limbs \[l\]-\[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh + Ih + Exh + Lh) + 0.2\*Au\*(Eu + Iu + ExU + Lu) + 0.3\*At\*(Et + It + Ext + Lt) + 0.4\*Al\*(El + Il + Exl +Ll); A = EASI area score. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. \>=75% improvement from baseline: decrease of 75% in EASI score from Baseline at Week 12.

Time frame:
Baseline (prior to dosing on Day 1), Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >= 75% Improvement From Baseline at Week 12: Main Study
Percentage of participantsMain Study: Abrocitinib 200 mgMain Study: Abrocitinib 100 mg
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >= 75% Improvement From Baseline at Week 12: Main Study71.7 (62.8 to 80.6)69.0 (59.9 to 78.1)
SecondaryPercentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >= 75% Improvement From Baseline at Week 12: Main Study

SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. Score for each body region was added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; lichenification; dryness) assessed as none =0, mild =1, moderate =2, severe =3. Severity scores were added to give B (0-18). C: pruritus and sleep, each was scored by participant/caregiver using visual analogue scale (VAS) where 0= no itch/no sleeplessness and 10= worst imaginable itch/sleeplessness. Scores for itch and sleeplessness were added to give C (0-20). Total SCORAD was calculated: A/5 + 7\*B/2 + C; total SCORAD range from 0-103; higher SCORAD scores = greater severity of AD. \>=75% improvement from baseline: decrease of 75% in SCORAD score from Baseline at Week 12.

Time frame:
Baseline (prior to dosing on Day 1), Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >= 75% Improvement From Baseline at Week 12: Main Study
Percentage of participantsMain Study: Abrocitinib 200 mgMain Study: Abrocitinib 100 mg
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >= 75% Improvement From Baseline at Week 12: Main Study47.5 (37.6 to 57.3)43.0 (33.3 to 52.7)
SecondaryChange From Baseline in Patient-Oriented Eczema Measure (POEM) Score at Weeks 2, 4, 8 and 12: Main Study

POEM is a 7-item participant reported outcome (PRO) measure to assess the impact of AD over the past week. Items were: dryness or roughness of skin in day, skin being itchy in day, skin flaking off in day, skin cracking in day, skin bleeding in day, skin weeping or oozing in day and sleep disturbed in night. Each item is scored from 0 to 4, depending on number of days/night (for sleep items) over the past week symptoms happened, where 0= no days, 1= "1-2 days", 2= "3-4 days", 3= "5-6 days" and 4= "every day". Scores from all items are added up, which results in POEM score, ranging from 0 to 28, where higher scores indicate greater severity of AD and greater symptom burden.

Time frame:
Baseline (prior to dosing on Day 1), Weeks 2, 4, 8 and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score at Weeks 2, 4, 8 and 12: Main Study
Units on a scaleMain Study: Abrocitinib 200 mgMain Study: Abrocitinib 100 mg
Week 2-6.3 ± 4.97-5.1 ± 5.12
Week 4-9.4 ± 5.42-8.1 ± 5.49
Week 8-12.0 ± 5.98-10.3 ± 5.55
Week 12-14.2 ± 5.88-12.4 ± 6.02
SecondaryChange From Baseline in Atopic Dermatitis Control Tool (ADCT) Score at Weeks 2, 4, 8 and 12: Main Study

ADCT score is used to measure the participants perceived AD control. It consists of 6 questions (overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions) which are evaluated over the past week on scale from 0 to 4. Scores from all 6 questions are added up to provide ADCT score, ranging from 0 to 24, where higher scores indicate lower AD control.

Time frame:
Baseline (prior to dosing on Day 1), Weeks 2, 4, 8 and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Atopic Dermatitis Control Tool (ADCT) Score at Weeks 2, 4, 8 and 12: Main Study
Units on a scaleMain Study: Abrocitinib 200 mgMain Study: Abrocitinib 100 mg
Week 2-5.2 ± 4.06-4.4 ± 4.57
Week 4-8.1 ± 4.90-7.4 ± 4.64
Week 8-10.7 ± 4.80-9.4 ± 5.21
Week 12-12.8 ± 5.33-11.5 ± 5.64
SecondaryPercentage of Participants With Bone Safety Findings in Knee Magnetic Resonance Imaging (MRI) at 1 Year After Randomization: Substudy

MRI imaging session was performed when participant was in supine position in the confined space of the MRI scanner for approximately 30 mins. The assessments included evaluation of epiphyseal plate closure and mineralization of cartilage at the growth centers.

Time frame:
Up to 1 year from randomization on Day 1 of main study
Reported as:
Number · Percentage of participants
Percentage of Participants With Bone Safety Findings in Knee Magnetic Resonance Imaging (MRI) at 1 Year After Randomization: Substudy
Percentage of participantsSubstudy: Abrocitinib 100 mgSubstudy: Abrocitinib 200 mg
Percentage of Participants With Bone Safety Findings in Knee Magnetic Resonance Imaging (MRI) at 1 Year After Randomization: Substudy0 (0.0 to 17.6)0 (0.0 to 20.6)

Adverse events

Collected over Main Study: From Day 1 of dosing up to 4 weeks post last dose (last dose at Week 12, maximum follow-up till Week 16); Sub Study: From Day 1 of dosing (in main study) up to 4 weeks post last dose (last dose at Year 1, maximum follow-up till Year 1.08). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Abrocitinib 200 mg QD0/99 (0%)0/99 (0%)22/99 (22.2%)
Main Study: Abrocitinib 100 mg QD0/101 (0%)1/101 (1%)20/101 (19.8%)
Substudy: Abrocitinib 100 mg0/19 (0%)0/19 (0%)8/19 (42.1%)
Substudy: Abrocitinib 200 mg0/16 (0%)0/16 (0%)5/16 (31.3%)
Most frequent serious events
Most frequent serious events
EventMain Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDSubstudy: Abrocitinib 100 mgSubstudy: Abrocitinib 200 mg
Radius fractureInjury, poisoning and procedural complications0/991/1010/190/16
Most frequent other events
Showing 10 of 23
Most frequent other events
EventMain Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDSubstudy: Abrocitinib 100 mgSubstudy: Abrocitinib 200 mg
PyrexiaGeneral disorders1/993/1011/192/16
Dermatitis atopicSkin and subcutaneous tissue disorders1/994/1011/192/16
NauseaGastrointestinal disorders9/995/1012/190/16
NasopharyngitisInfections and infestations0/990/1012/191/16
CoughRespiratory, thoracic and mediastinal disorders1/993/1011/191/16
GastritisGastrointestinal disorders0/990/1010/191/16
AsthmaRespiratory, thoracic and mediastinal disorders0/990/1010/191/16
HypotensionVascular disorders0/990/1010/191/16
DizzinessNervous system disorders0/990/1010/191/16
PharyngitisInfections and infestations0/990/1010/191/16

Baseline characteristics

Safety analysis set included all participants randomly assigned to study intervention and who had taken at least 1 dose of study intervention. Participants were analyzed according to the treatment they actually received. Substudy analysis set (SAS) included all participants who entered the substudy and who took at least 1 dose of study intervention during the substudy.

Age, Continuous
Age, Continuous(Years)Main Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDTotal
Main Study35.37 ± 17.1937.50 ± 17.4936.45 ± 17.33
Substudy14.79 ± 2.2514.44 ± 1.3614.63 ± 1.88
Sex: Female, Male
Sex: Female, Male(Participants)Main Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDTotal
Main Study — Female6148109
Main Study — Male385391
Substudy — Female12719
Substudy — Male7916
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDTotal
Main Study — Hispanic or Latino000
Main Study — Not Hispanic or Latino99101200
Main Study — Unknown or Not Reported000
Substudy — Hispanic or Latino000
Substudy — Not Hispanic or Latino191635
Substudy — Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Study: Abrocitinib 200 mg QDMain Study: Abrocitinib 100 mg QDTotal
Main Study — American Indian or Alaska Native000
Main Study — Asian99101200
Main Study — Native Hawaiian or Other Pacific Islander000
Main Study — Black or African American000
Main Study — White000
Main Study — More than one race000
Main Study — Unknown or Not Reported000
Substudy — American Indian or Alaska Native000
Substudy — Asian191635
Substudy — Native Hawaiian or Other Pacific Islander000
Substudy — Black or African American000
Substudy — White000
Substudy — More than one race000
Substudy — Unknown or Not Reported000
08

Study locations

15 sites
  • All India Institute of Medical Sciences
    New Delhi, Delhi 110029, India
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110060, India
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • Government Medical College & Shri Sayajirao General Hospital
    Vadodara, Gujarat 390001, India
  • RajaRajeswari Medical College and Hospital
    Bengaluru, Karnataka 560074, India
  • Father Muller Medical College Hospital
    Mangalore, Karnataka 575002, India
  • Mahatma Gandhi Mission's Medical College & Hospital
    Aurangabad, Maharashtra 431003, India
  • Orange City Hospital and Research Institute
    Nagpur, Maharashtra 440015, India
  • Assured Care Plus Hospital
    Nashik, Maharashtra 422101, India
  • Jehangir Clinical Development Centre Pvt. Ltd.
    Pune, Maharashtra 411001, India
  • S. P. Medical College & A. G. Hospitals
    Bikaner, Rajasthan 334001, India
  • Apex Hospitals Pvt. Ltd.
    Jaipur, Rajasthan 302017, India
  • Calcutta School of Tropical Medicine
    Kolkata, WEST Bengal 700073, India
  • Postgraduate Institute of Medical Education & Research
    Chandigarh, 160012, India
  • Maharaja Agrasen Hospital
    New Delhi, 110026, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jun 2023, 10 months.

Results were first posted in Sep 2024, 1 year 3 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2022
First posted
May 17, 2022
StartActual
Jul 16, 2022
Primary completionActual
Jun 9, 2023
CompletionActual
Mar 14, 2024
Results first posted
Sep 19, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05375929
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 17, 2022
Start date
Jul 16, 2022
Primary completion
Jun 9, 2023
Completion
Mar 14, 2024
Results posted
Sep 19, 2024
Last update
Oct 15, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion